Screener / SEC EDGAR /CIK 0001588978 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

PROCEPT BioRobotics Corp PRCT

Compare with peers Embed
Planned sales, announced before they happen

1 trading plan running, 13 Form 144 notices for $717K

10-Q, 10-K and Form 144

What PRCT's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Feb 29, 2024 to Jun 17, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Kevin Waters
Chief Financial Officer
Adopted 10b5-1 plan Mar 18, 2026 10-Q Apr 30, 2026
What the company wrote
On March 18, 2026, Kevin Waters, the Company’s Chief Financial Officer, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Waters Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock. The Waters Rule 10b5-1 Plan was entered into in accordance with the Company’s policies regarding transactions and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Waters Rule 10b5-1 Plan provides for the potential sale of up to 59,127 shares of the Company’s common stock during various specified trading periods through June 17, 2027.
Alaleh Nouri
Chief Legal Officer
Ended 10b5-1 plan Jun 3, 2025 10-Q Aug 7, 2025
What the company wrote
On June 4, 2025, Alaleh Nouri adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “2025 Nouri Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act stock. The 2025 Nouri Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions. The 2025 Nouri Rule 10b5-1 Plan provides for the potential sale of up to a maximum of 70,836 shares of the Company’s common stock during various specified trading periods through September 7, 2026.
Reza Zadno
Chief Executive Officer
Adopted 10b5-1 plan Jun 3, 2025 10-Q Aug 7, 2025
What the company wrote
On June 3, 2025, Reza Zadno, the Company’s Chief Executive Officer, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Zadno Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act stock. The Zadno Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions. The Zadno Rule 10b5-1 Plan provides for the potential sale of up to 76,978 shares of the Company’s common stock during various specified trading periods through December 17, 2025.
Antal Desai
Adopted 10b5-1 plan Nov 21, 2024 10-K Feb 27, 2025
What the company wrote
On November 21, 2024, Antal Desai, a member of the Company’s Board of Directors, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Desai Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock held by the 2:22 DNA Trust. The Desai Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Desai Rule 10b5-1 Plan provides for the potential sale of up to 150,000 shares of the Company’s common stock during various specified trading periods through June 13, 2025.
Alaleh Nouri
Chief Legal Officer
Adopted 10b5-1 plan Sep 3, 2024 10-Q Oct 28, 2024
What the company wrote
On September 3, 2024, Alaleh Nouri, the Company’s Chief Legal Officer, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Nouri Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock. The Nouri Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Nouri Rule 10b5-1 Plan provides for the potential sale of up to 56,185 shares of the Company’s common stock during various specified trading periods through December 31, 2025.
Reza Zadno
Company’s Chief Executive Officer
Adopted 10b5-1 plan Aug 8, 2024 10-Q Oct 28, 2024
What the company wrote
On August 8, 2024, Reza Zadno, the Company’s Chief Executive Officer, adopted a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Zadno Rule 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act stock. The Zadno Rule 10b5-1 Plan was entered into during an open trading window in accordance with the Company’s policies regarding transactions. The Zadno Rule 10b5-1 Plan provides for the potential sale of up to 105,683 shares of the Company’s common stock during various specified trading periods through December 4, 2024.
Kevin Waters
Chief Financial Officer
Adopted 10b5-1 plan Jun 13, 2024 10-Q Aug 2, 2024
Antal Desai
Company’s Board of Directors
Adopted 10b5-1 plan May 30, 2024 10-Q Aug 2, 2024
Alaleh Nouri
Chief Legal Officer
Adopted 10b5-1 plan Mar 13, 2024 10-Q/A Jun 27, 2024
Sham Shiblaq
Chief Commercial Officer
Adopted 10b5-1 plan Mar 9, 2024 10-Q/A Jun 27, 2024
Frederic Moll
M.D., the Chair of the Company’s Board of Directors
Adopted plan Feb 29, 2024 10-Q May 2, 2024
What the company wrote
On February 29, 2024, Frederic Moll, M.D., the Chair of the Company’s Board of Directors, terminated a pre-arranged written stock sale plan in accordance with Rule 10b5-1 (the “Moll 10b5-1 Plan”) under the Exchange Act, for the sale of shares of the Company’s common stock. The Moll 10b5-1 Plan was terminated during an open trading window in accordance with the Company’s policies regarding transactions in the Company’s securities and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The Moll 10b5-1 Plan provided for the potential sale of up to 237,000 shares of the Company’s common stock, so long as the market price of the Company’s common stock was higher than certain minimum threshold prices specified in the Moll 10b5-1 Plan. The Moll 10b5-1 Plan was to expire on December 31, 2024, or on such earlier date on which all of the trades thereunder had been executed.
Frederic Moll, M.D.
Chair of the Company’s Board of Directors
Ended 10b5-1 plan Feb 29, 2024 10-Q/A Jun 27, 2024
Show the other 4 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 17 filings checked since May 4, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 6, 2026 Sharma Pooja
Officer
4,710 $93K
Sep 9, 2026 Nouri Alaleh
Officer
297 $6K
Sep 9, 2026 Templin Barry L
Officer
373 $8K
Sep 9, 2026 Waters Kevin
Officer
373 $8K
Jun 8, 2026 Nouri Alaleh
Officer
285 $8K
Jun 8, 2026 Waters Kevin
Officer
357 $10K
Jun 8, 2026 Templin Barry L
Officer
358 $10K
Mar 19, 2026 Alalah Nouri
Officer
5,363 $140K
Mar 17, 2026 Nouri Alaleh
Officer
304 $9K
Mar 17, 2026 Waters Kevin
Officer
706 $20K
Mar 10, 2026 Alalah Nouri
Officer
3,243 $82K
Mar 6, 2026 Nouri Alaleh
Officer
6,892 $163K
Mar 6, 2026 Waters Kevin
Officer
6,721 $159K
Show the other 5 notices

From the Form 144 XML filed with the SEC, since Mar 6, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRCT/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.